195252-62-1

Basic information

• Product Name: 6-chloro-N4-cyclopropylpyrimidine-4,5-diamine
• Synonyms: 6-chloro-N4-cyclopropylpyrimidine-4,5-diamine;6-chloro-4-N-cyclopropylpyrimidine-4,5-diamine
• CAS NO: 195252-62-1
• Molecular Formula: C7H9ClN4
• Molecular Weight: 184.62616
• Mol File: 195252-62-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-N4-cyclopropylpyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N4-cyclopropylpyrimidine-4,5-diamine(195252-62-1)
• EPA Substance Registry System: 6-chloro-N4-cyclopropylpyrimidine-4,5-diamine(195252-62-1)

Safety Data

• Hazardous Substances Data: 195252-62-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-chloro-N4-cyclopropylpyrimidine-4,5-diamine is used as an enzyme inhibitor for the development of new pharmaceuticals. Its ability to inhibit specific enzymes makes it a promising candidate for the treatment of various diseases.
Used in Cancer Treatment:
6-chloro-N4-cyclopropylpyrimidine-4,5-diamine is used as a potential cancer treatment agent. Its potent enzyme inhibitory properties have been studied for their potential to target and treat cancer cells, offering a new avenue for cancer therapy.
Used in Treatment of Other Diseases:
6-chloro-N4-cyclopropylpyrimidine-4,5-diamine is used as a potential therapeutic agent for the treatment of other diseases. Its unique structure and properties make it a valuable tool for exploring new treatment options for a variety of medical conditions.

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 765-30-0 Cyclopropylamine 

Downstream Products

• 1241490-96-9 6-(4-chlorophenyl)-N-cyclopropylpyrimidine-4,5-diamine 
• 195252-29-0 Cyclopropyl-(9-cyclopropyl-9H-purin-6-yl)-amine 
• 6627-30-1 6-chloro-9-cyclopropyl-9H-purine 

Relevant articles and documents

Projected Dose Optimization of Amino- And Hydroxypyrrolidine Purine PI3KδImmunomodulators

The approvals of idelalisib and duvelisib have validated PI3Kδinhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors wit

INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

Efficient synthesis of purine analogues: An FeCl3-SiO2-promoted cyclization reaction of 4,5-diaminopyrimidines with aldehydes leading to 6,8,9-trisubstituted purines

6,8,9-Trisubstituted purine analogues were efficiently synthesized via cyclization of 6-chloro-4,5-diaminopyrimidines and various aldehydes promoted by FeCl3-SiO2. Fe(III) chloride on silica gel has a dual role of a dehydration agent

6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents

A series of 6-(alkylamino)-9-alkylpurines was synthesized and evaluated for the property of antagonizing the behavioral effects in animals of the dopamine agonist apomorphine. This model for identifying potential antipsychotic agents is based on the hypothesis that agents that antagonize apomorphine-induced aggressive behavior in rats and apomorphine-induced climbing in mice, but that do not block stereotyped behavior, could have an antipsychotic effect in humans without producing extrapyramidal side effects. The antiaggressive-behavior activity of lead compound 1 (6-(dimethylamino)- 9-(3-phenylalaninamidobenzyl)-9H-purine) was improved 48-fold with 6- (cyclopropylamino)-9-(cyclopropylmethyl)-2-(trifluoromethyl)-9H-purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterative sequence of structure-activity relationship studies that encompassed evaluation of the effects of structure variations at the purine 9-, 6-, and 2-positions. Potency was enhanced with a 9-cyclopropyl group, the duration of action was improved with the 6-(cyclopropylamino) substituent, potency was further enhanced with an N-formyl prodrug, and an agent with reduced cardiovascular effect emerged with the 2-trifluoromethyl purine 80. This potential antipsychotic agent was not developed further due to undesirable effects on the stomach.